Healthcare
May 9, 2019
Washington, D.C. — Today, Congressman Doggett (D-TX), Chairman of the House Ways and Means Health Subcommittee, responded to President Trump’s expected call to action regarding surprise medical bills today. Fifty-seven percent of American adults have received a surprise bill for expenses that they thought would have been covered by insurance. Rep. Doggett has authored the only legislation in the House to end this unjustified practice. His statement:
Issues:Healthcare
April 29, 2019
Washington, D.C. – Today, the Congressional Progressive Caucus (CPC) announced its endorsement of H.R. 1046, the Medicare Negotiation and Competitive Licensing Act of 2019, introduced by Congressman Lloyd Doggett (TX-35).
April 18, 2019
As drug prices have soared, lawmakers and patient advocates have pushed the federal government to deploy for the first time a powerful deterrent: a legal provision that allows it to suspend a drugmaker’s patent and license someone else to produce the drug.
Issues:Healthcare
March 27, 2019
The Trump administration has held early-stage conversations with Speaker Nancy Pelosi's staff about drug-pricing legislation that could provide each side with a domestic policy victory, according to White House and congressional sources.
Issues:Healthcare
March 27, 2019
Democrats are seeking to move beyond special counsel Robert S. Mueller III’s report to a different action taken this week by the Justice Department: its statement supporting Texas’ legal challenge to the 2010 health care law, which said the entire act should fall.
Issues:Healthcare
March 26, 2019
Washington, DC — Today, Congressman Lloyd Doggett (D-Texas) questioned the Health and Human Services Deputy Secretary Eric Hargan in a Budget Committee hearing, after Secretary Azar declined to testify. Rep. Doggett asked Deputy Secretary Hargan why the Trump Administration’s budget declines to invest in lowering the price of prescription drugs or empowering Medicare to negotiate, as President Trump called for when he was Candidate Trump. Specifically, Rep. Doggett asked about the overdose prevention drug naloxone and was told by the Trump Administration witness that there was no affordability problem. You can watch the exchange here, or read the excerpts below. After the hearing Rep. Doggett stated: “It is difficult to agree on how to solve the problem of high prescription drug prices when Trump’s HHS does not even acknowledge the crisis exists.”
Issues:Healthcare
March 7, 2019
House Democrats on Thursday took aim at one of the pharmaceutical industry’s key arguments as Congress considers how to address drug prices, questioning whether drugmakers are actually innovating in exchange for the high prices Americans pay.
Issues:Healthcare
March 7, 2019
Washington, DC — Today, Chairman Doggett held a Ways and Means Health Subcommittee hearing on medicines in Medicare. Hearing from experts testifying to policy options and patient experience, it explored ways that Medicare can encourage affordability, competition, and access to medicines, as patients face a prescription drug affordability crisis. It featured expert witnesses Frederick Isasi, Executive Director, Families USA; Robin Feldman, Director of the Institute for Innovation Law, UC Hastings College of Law; Ameet Sarpatwari, Assistant Director of the Program on Regulation, Therapeutics, and Law (PORTAL) Harvard Medical School; Amy Kapczysnki, Co-Director of the Global Health Justice Partnership, Yale Law School; and Douglas Holtz-Eakin, President, American Action Forum.
March 7, 2019
From News 4 San Antonio on our hearing today on soaring Rx drug prices & promoting competition to ensure access to medicines:
Issues:Healthcare
February 28, 2019
WASHINGTON, DC – House Ways and Means Health Subcommittee Chairman Lloyd Doggett announced today that the Subcommittee will hold a hearing, entitled “Promoting Competition to Lower Medicare Drug Prices” on Thursday, March 7, 2019, at 10:00 a.m. in room 1100 Longworth House Office Building.
Issues:Healthcare